Pharmaceutical Technology

JANUARY 10, 2023

In addition, market growth will be driven by dapagliflozin (Farxiga) in the SGLT-2I space, and novel GLP-1/GIP Mounjaro (tirzepatide), biosimilar/interchangeable insulins such as insulin lispro and insulin glargine (Basaglar), and the launch of once-weekly insulins icodec and Icosema, forecast for 2024 launch.

Insulin 130

Insulin Marketing Sales Compliance 130

Pharmaceutical Technology

APRIL 14, 2023

Among several growth-promoting supplements added to the cell culture media formulations, insulin is one of the most common. Recombinant insulin is used as a supplement in the upstream manufacturing of a range of biologic drugs, including recombinant proteins, such as monoclonal antibodies, viral vectors, and viruses.

Insulin 130

Insulin Production Antibody Protein 130

STAT News

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments. The company plans to cut the list price of its NovoLog insulin by 75%, and the prices for Novolin and Levemir by 65% starting in January 2024.

Insulin 98

Insulin Branding Production Drugs 98

XTalks

NOVEMBER 15, 2022

In Lilly’s case, the fake account claimed the company was giving out free insulin. A fraudulent Eli Lilly account with the username @EliLillyandCo tweeted a message on November 10 that said: “We are excited to announce insulin is free now.”. On average, it is estimated that insulin costs about $98.70 percent, or by $16.08

Insulin 97

Insulin Sales Branding Production 97

pharmaphorum

NOVEMBER 11, 2022

Almost immediately Twitter trolls and pranksters began using the new service to impersonate brands and individuals. In addition to the financial hit, the stunt has only served to draw attention to Lilly’s role in the insulin pricing crisis in the United States, where multiple patients have died because of rationing unaffordable insulin.

Insulin 98

Insulin Branding Production Marketing 98

pharmaphorum

JULY 29, 2021

Generic drugmaker Mylan has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi’s once-daily insulin Lantus. Biosimilars marketed in the US typically have list prices 15% to 35% lower than their reference products at launch.

Insulin 98

Insulin Drugs Production Generic Drugs 98

STAT News

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments , STAT writes. The Novo will also lower prices for its unbranded insulin products to match the reduced price of its corresponding brand-name insulin treatments. The

Insulin 98

Insulin Production Branding 98

World of DTC Marketing

JUNE 7, 2021

Retail price increases for widely used brand name prescription drugs consistently exceeded the rate of general inflation between 2006 and 2020. In 2020, retail prices for 260 brand-name prescription drugs widely used by older adults increased by an average of 2.9 A perfect example of industry pricing issues is insulin.

Insulin 187

Insulin Branding Drugs Production 187

Fierce Pharma

MARCH 14, 2024

Biocon and Eris have expanded a previous agreement, with Biocon selling Indian branded formulations businesses to Mumbai-based Eris for $150M.

Branding 72

Branding Insulin Sales 72

Drug Channels

NOVEMBER 9, 2021

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. However, only the high-list/high-rebate, branded version will be available on Express Scripts’ largest commercial formulary. Read the FDA’s press release.

Insulin 75

Insulin Branding Production Drugs 75

XTalks

AUGUST 29, 2024

The recent US Food and Drug Administration (FDA) clearance of the Omnipod 5 Automated Insulin Delivery (AID) System for people with type 2 diabetes marks a significant milestone in diabetes care. The Omnipod 5 system offers a personalized approach to insulin delivery, integrating CGM with adaptive insulin administration.

Insulin 59

Insulin Branding Development Drugs 59

Drug Channels

APRIL 19, 2022

Anyone want to tell him about the Express Scripts formulary for insulin biosimilars? The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release.

Insulin 75

Insulin Branding Production Drugs 75

Pharmaceutical Technology

APRIL 10, 2023

India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026.

Branding 130

Branding Drugs Insulin Production 130

Drug Patent Watch

JANUARY 13, 2025

.” Diabetes: Addressing a Global Epidemic With diabetes affecting millions worldwide, the advent of biosimilar insulins has been particularly impactful. The future of biosimilars may lie in their integration with personalized medicine approaches, potentially leading to more targeted and effective treatments.

Marketing 78

Marketing Insulin Generic Drugs Medicine 78

World of DTC Marketing

DECEMBER 16, 2021

Pharma CEOs also continue to take in tens of millions of dollars in compensation while people often pay close to $1000 for insulin. Of course, the irony of this data is that it negates PhRMAs key argument against having the government negotiate prices for Medicare. How immoral is the profiteering?

Insulin 205

Insulin Pharma Companies Drugs Branding 205

The Pharma Data

SEPTEMBER 30, 2021

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S.

Insulin 52

Insulin Pharmacy Branding Medicine 52

XTalks

MARCH 15, 2024

The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab). It is estimated that more than 8 million Americans rely on insulin products to manage their diabetes.

Pharmacy 111

Pharmacy Drugs Insulin Branding 111

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S.

Insulin 52

Insulin Production FDA Approval Generic Drugs 52

FDA Law Blog

AUGUST 12, 2021

On July 30, 2021, FDA approved Semglee (insulin glargine-yfgn), an insulin product that relies on Lantus (insulin glargine) as its reference product. So, it remains to be seen if and when interchangeable Semglee will have any meaningful effect on insulin prices in the near future.

Insulin 98

Insulin Production FDA Approval Marketing 98

Pharmaceutical Technology

JUNE 29, 2022

In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. The enzymes must be manufactured under cGMP conditions – completely free of animal-derived ingredients.”. Developing best-in-class speciality enzymes. And it’s within the family – Novozymes!”.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

World of DTC Marketing

JUNE 16, 2021

The pharma industry has been riding a wave of public approval since they developed a vaccine to fight COVID-19, but that goodwill is going to be short lived thanks, in part, to the $56,000 price tag of Biogen’s new drug and insulin that too many people still can’t afford. But changes are coming; it’s only a matter of time.

Drugs 180

Drugs Branding Medicine Insulin 180

Drug Channels

AUGUST 11, 2020

Consistent with our previous analyses, rebates and discounts reduced the selling price of brand-name drugs to about half of their list prices. As the companies’ insulin data illustrate below, the bubble raises costs for patients who are not always benefiting from lower net selling prices.

Insulin 52

Insulin Branding Drugs Manufacturing 52

Druggist

MAY 6, 2021

Beta-cells : cells present in the pancreas, which produce insulin. Insulin: a hormone that allows glucose (sugar) to be used for energy in the body. Lastly, metformin improves sensitivity to insulin (Wiernsperger & Bailey, 1999), which regulates body sugar levels. Metformin does not increase insulin release.

Insulin 98

Insulin Branding Drugs Licensing 98

pharmaphorum

JULY 5, 2022

The medicines – which include insulin, oral diabetes agent glibenclamide and cancer chemotherapy oxaliplatin – will be sold under a new Impact brand and are all classed as essential medicines by the World Health Organisation (WHO).

Medicine 119

Medicine Insulin Branding Vaccination 119

pharmaphorum

NOVEMBER 15, 2022

It seems Lilly might have cut Twitter some slack if it had responded promptly to its frantic attempts to get the post – put up by someone who paid $8 to verify the imposter @EliLillyandCo account – which claimed that “insulin is free now.”

Insulin 98

Insulin Branding Sales Marketing 98

pharmaphorum

NOVEMBER 8, 2022

The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart Button device that stores and transfers insulin dose-related data from the pen, and can link with compatible devices. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 64

Insulin Marketing Branding Manufacturing 64

The Pharma Data

MAY 6, 2021

The Tempo Pen is a modified version of Lilly ‘s existing prefilled, disposable insulin pen to which the Tempo Smart Button – pending CE (Conformité Européenne or European Conformity) marking – attaches. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin. About DexCom Inc.

Insulin 52

Insulin Medicine Production Hormones 52

Drug Channels

OCTOBER 1, 2024

of the complaint (starting on page 23) focuses on the PBMs’ alleged unlawful conduct related to preferring high-list/high-rebate insulin products over versions with lower list prices. However, only the high-list/high-rebate, branded version will be available on Express Scripts’ largest commercial formulary. Section V.E.

Insulin 40

Insulin Branding Production Pharmacy 40

Pharmaceutical Technology

DECEMBER 4, 2022

For example, the first-to-market status was beneficial when it came to insulin biosimilars. Citing studies comparing such products, there are no important differences between biosimilars and their branded counterpart, says Arnold Vulto, PharmD, professor of hospital pharmacy at Erasmus University, Rotterdam.

Marketing 262

Marketing Pharmacy Production Branding 262

XTalks

FEBRUARY 8, 2021

Like generic forms of synthetic pharmaceuticals, biosimilars have the advantage of being less costly compared to their branded counterparts. Some prescribers and pharmacists have been hesitant to give patients biosimilar forms of biologic drugs over concerns that they may not be as safe or effective as the branded product.

Production 78

Production Insulin Branding Generic Drugs 78

XTalks

DECEMBER 14, 2022

CGMs can alert diabetics sufficiently in advance of too high or low blood glucose levels, allowing the wearer to improve the situation with insulin, for example. The CGM can be integrated with insulin delivery systems and connected to devices like Apple watches and popular health apps. Dexcom, Inc. , a cellphone) every five minutes.

Insulin 98

Insulin Marketing Branding Life Science 98

STAT News

NOVEMBER 18, 2022

The monoclonal antibody teplizumab, which will be marketed under the brand name Tzield and is from ProventionBio and Sanofi, is given through intravenous infusion. Diabetic patients will now have easier access to insulin after the FDA approved an Eli Lilly biosimilar as interchangeable with the biologic drug , Bloomberg News notes. Rezvoglar,

Insulin 98

Insulin FDA Approval Production Pharmacy 98

Drug Channels

JULY 23, 2024

These data remain inconvenient for drug pricing flat earthers (#DPFE): When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2023. Rebates and discounts reduced the selling prices of brand-name drugs at the biggest drugmakers to less than half of their list prices.

Branding 52

Branding Insulin Drugs Manufacturing 52

XTalks

MAY 13, 2021

Taking advantage of the opportunity, the top ten pharma brands spent 17 percent more on TV ads in April 2020 compared to just a month prior, raising their monthly ad expenditures from $156 million to $183 million. When a lot of brands are advertising simultaneously, linear TV helps you maintain awareness across your audience segment.”.

Insulin 104

Insulin Marketing Drugs Branding 104

BioTech 365

NOVEMBER 24, 2021

–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that … Continue reading →

Insulin 40

Insulin Branding Production 40

BioTech 365

NOVEMBER 1, 2021

–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand … Continue reading →

Insulin 40

Insulin Branding 40

BioTech 365

APRIL 29, 2021

–(BUSINESS WIRE)–Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of … Continue reading →

Insulin 40

Insulin Branding 40